Sunitinib in combination with docetaxel in patients with advanced solid tumors: A phase I dose-escalation study

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 4, 2010, Pages 669-680

  Robert, Francisco ^a   Sandler, Alan ^b   Schiller, Joan H ^c   Liu, Glenn ^d   Harper, Karen ^a   Verkh, Lev ^e   Huang, Xin ^e   Ilagan, Jennifer ^e   Tye, Lesley ^e   Chao, Richard ^e   Traynor, Anne M ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e PFIZER INC   (United States)

Author keywords

Antiangiogenesis; Docetaxel; NSCLC; Phase I; Solid tumors; Sunitinib

Indexed keywords

DOCETAXEL; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TAXOID;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPESTHESIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OBSTRUCTIVE AIRWAY DISEASE; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; VULVOVAGINITIS; AREA UNDER THE CURVE; BIOASSAY; DOSE RESPONSE; DRUG COMBINATION; HALF LIFE TIME; MIDDLE AGED; NEOPLASM; ADVANCED CANCER; BLOOD TOXICITY; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEART LEFT VENTRICLE EJECTION FRACTION; QT INTERVAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HALF-LIFE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; PYRROLES; TAXOIDS;

EID: 78149356321     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1209-0     Document Type: Article

References (32)

1. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121:2606-2614
2. Potapova O, Laird AD, Nannini MA et al (2006) Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5:1280-1289
3. Shikada Y, Yonemitsu Y, Koga T et al (2005) Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 65:7241-7248
4. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
5. Manegold C, Von Pawel J, Zatloukal P et al. (2008) BO17704 (AVAIL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol 19: viii1 (Abstract LBA1)
6. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229-239
7. Sanofi-aventis (2007) Taxotere (docetaxel) Prescribing Information. Sanofi-aventis, New York
8. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
9. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24
10. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
11. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
12. Kim DW, Jo YS, Jung HS et al (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076
13. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
14. Murray LJ, Abrams TJ, Long KR et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766
15. O'Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605
16. Pfizer Inc (2008) Data on file
17. Kulke M, Lenz HJ, Meropol N et al (2008) Activity of Sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410
18. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
19. Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancer. J Clin Oncol 26:650-656
20. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
21. Abrams TJ, Murray LJ, Pesenti E et al (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021
22. Christensen JG, Hall C, Hollister BA (2008) Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. Proceedings of the 99th annual meeting of the American association for cancer research
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
24. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
25. Schoffski P, Dumez H, Clement P et al (2006) Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17:1185-1196
26. SUTENT (2008) (Sunitinib malate) prescribing information. New York, NY
27. Gianni L, Cardoso F, Mariani G, Isaksson-Friman E, Besse-Hammer T, Vigano L, Verkh L, Rossi, C, Giorgetti C, Bergh J (2007) Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer. Br Cancer Res Treat 106 (Suppl. 1): S273 (Abstract 6079)
28. Fossella FV, De Vore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362
29. Harvey V, Mouridsen H, Semiglazov V et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970
30. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
31. Scagliotti G, Von Pawel J, Reck M, Cupit L, Cihon F, Di Matteo S, O'Leary, J, Hanna N (2008) Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIb-IV NSCLC: interim analysis results form the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, CArboplatin and Paclitaxel Efficacy in NSCLC) trial
32. Laurie SA, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Goss G, Ding K, Seymour L (2008) National Cancer Institute of Canada clinical trials group study BR.24, a randomized placebo controlled phase II trial of cediranib (CED) plus carboplatin - paclitaxel (C-P) in advanced non-small cell lung cancer of any histology: further analyses. J Thorac Oncol 3 (11 (Supplement 4)): S262